オカザキ　ケン   OKAZAKI Ken   岡崎　賢    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Responders and non-responders to romosozumab treatment.
掲載誌名	正式名：Journal of bone and mineral metabolism 略　 称：J Bone Miner Metab ISSNコード：14355604/09148779
掲載区分	国外
巻・号・頁	43(1),pp.18-21
著者・共著者	Tominaga Ayako, Wada Keiji, Kato Yoshiharu, Okazaki Ken
担当区分	最終著者
発行年月	2025/01
概要	INTRODUCTION:Romosozumab is an anti-sclerostin antibody drug with potent bone formation-promoting and bone resorption-inhibiting properties. It enhances bone mineral density and has a novel effect in preventing fractures. However, there have been reports of non-responders to romosozumab.FINDINGS:If the least significant change is defined as 3%, only 2-12% of patients with spine osteoporosis are non-responders, and romosozumab is highly effective in this population. Low-type 1 amino-terminal propeptide (P1NP) levels during the early treatment phase are associated with non-responders early in treatment. The researchers found a cutoff value of 50.3 μg/L of P1NP in the first month of treatment. In contrast, hip osteoporosis does not respond (54-57% of the time). Low P1NP levels at the start of treatment increase the risk of non-responders. The cutoff value for P1NP was reported as 53.7 μg/L at the beginning of treatment. However, failure to meet these cutoff values does not necessarily indicate that the patient is a non-responder and does not justify a change in drug administration.CONCLUSIONS:In spine osteoporosis, romosozumab demonstrates high effectiveness, with approximately 2-12% of patients showing no response. However, in hip osteoporosis, approximately 54-57% do not respond to the treatment with romosozumab.
DOI	10.1007/s00774-024-01570-y
PMID	39645533